More topics

Limited Coverage Drugs – romosozumab

Last updated on February 6, 2024

Generic name

romosozumab

Strength

105 mg/1.17 mL 

Form

pre-filled syringe

Special Authority criteria

Approval period

For the treatment of osteoporosis in postmenopausal women who:

  • Have sustained an osteoporotic fracture

AND

  • Are at high risk for future fracture, defined as 10-year fracture-risk ≥ 20% as defined by the Fracture Risk Assessment (FRAX) tool

AND

  • Are treatment naive to osteoporosis medications, except for calcium and/or vitamin D

AND

  • Will not be prescribed other osteoporosis medications concurrently with romosozumab, except for calcium and/or vitamin D

Up to 12 months1

Practitioner exemptions

  • None

Special notes

  1. The maximum duration of coverage is 12 months. Coverage for retreatment with romosozumab will not be provided
  2. If patient has had any romosozumab therapy prior to being approved for coverage by PharmaCare, it is expected that the total duration of therapy does not exceed 12 months
  3. PharmaCare covers a maximum of 30 days of romosozumab per fill
  4. PharmaCare coverage is limited to 210 mg of romosozumab monthly

Special Authority requests